Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Garo Armen
|
| gptkbp:collaboratedWith |
gptkb:Gilead_Sciences
gptkb:Incyte_Corporation |
| gptkbp:developedBy |
cancer vaccines
checkpoint inhibitors antibody therapies |
| gptkbp:focusesOn |
immuno-oncology
immunotherapy |
| gptkbp:foundedIn |
1994
|
| gptkbp:founder |
Garo Armen
|
| gptkbp:headquartersLocation |
gptkb:Lexington,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Agenus
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
QS-21 Stimulon
balstilimab zalifrelimab |
| gptkbp:publiclyTraded |
NASDAQ: AGEN
|
| gptkbp:subsidiary |
Agenus West
|
| gptkbp:tradedOn |
AGEN
|
| gptkbp:website |
https://agenusbio.com/
|
| gptkbp:bfsParent |
gptkb:Linda_Powers
|
| gptkbp:bfsLayer |
8
|